McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine Deal

McKesson NYSE: MCK executives said the company's first-quarter performance supported a higher full-year earnings outlook, citing broad-based growth across its North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions businesses.

MarketBeat • Sep 14, 2026

McKesson Corporation (MCK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

McKesson Corporation (MCK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 14, 2026

PRIVACY ALERT: AWKO Law LLP Investigating McKesson for Data Breach Affecting 284 Million Patient Records

SAN FRANCISCO--(BUSINESS WIRE)--AWKO Law LLP is investigating a data breach that led to unauthorized access to the sensitive information of 284 million patient records affiliated with McKesson Corporation (“McKesson”), a Texas-based distributor of pharmaceuticals and provider of health information technology, medical supplies, and health management tools.On August 28, 2026, McKesson disclosed to the Securities and Exchange Commission (“SEC”) that it had been the subject of a cybersecurity incide.

Business Wire • Sep 10, 2026

McKesson (MCK) Suffers a Larger Drop Than the General Market: Key Insights

McKesson (MCK) closed at $880.86 in the latest trading session, marking a -1.21% move from the prior day.

Zacks Investment Research • Sep 10, 2026

McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It

McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Investment Research • Sep 9, 2026

McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates

McKesson NYSE: MCK discussed its planned $2.25 billion acquisition of Precision Medicine Group, first-quarter operating trends and capital-allocation priorities during a presentation with Wells Fargo analyst Stephen Baxter.

MarketBeat • Sep 8, 2026

McKesson Corporation (MCK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

McKesson Corporation (MCK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Seeking Alpha • Sep 8, 2026

Underestimating The Moat: Why McKesson's Oncology Pivot And Share Buybacks Signal Structural Upside

McKesson operates within a US pharma distribution oligopoly, generating $5B+ in FCF and aggressively repurchasing shares. The oncology segment is driving growth, with a 31% YoY revenue increase and strategic acquisitions reinforcing the shift toward higher-margin businesses. Despite negative shareholder equity from buybacks and opioid liabilities, MCK maintains strong liquidity, low leverage, and disciplined capital returns.

Seeking Alpha • Sep 8, 2026

Why Is McKesson (MCK) Up 5.7% Since Last Earnings Report?

McKesson (MCK) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 4, 2026

Here's Why McKesson (MCK) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Sep 3, 2026